Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...

Immix Biopharma (IMMX) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL ...

Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –– CR rate now 95% (19 of 20 patients) –– ...

Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ...

Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging agent that could accelerate the ...

Davies said other early warning signs of amyloidosis can include spinal stenosis, rotator cuff injuries, hip and knee replacements, peripheral neuropathy, lightheadedness from drops in blood pressure ...

Amyloidosis is classified into three main forms depending on the cause of the condition. The condition is also referred to as either localized when only one site of the body is affected, or systemic ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

In most cases, AA amyloidosis starts in the liver. In response to infection or inflammation, the liver produces high levels of SAA. These SAA proteins help carry immune cells to inflamed parts of the ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its ...